Publication Name	World Journal of Gastroenterology
Manuscript ID	29107
Country	Lebanon

Received	2016-07-29 09:53
Peer-Review Started	2016-08-02 20:04
First Decision by Editorial Office Director
Return for Revision	2017-03-09 19:30
Revised
Publication Fee Transferred
Second Decision by Editor	2017-03-24 12:19
Second Decision by Editor-in-Chief	2017-03-25 18:25
Final Decision by Editorial Office Director	2017-03-31 07:47
Articles in Press	2017-03-31 07:47
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-04-21 11:22
Publish the Manuscript Online	2017-05-06 20:30

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality
Manuscript Source	Invited Manuscript
All Author List	Hampig Raphael Kourie, Samer Tabchi and Marwan Ghosn
Funding Agency and Grant Number
Corresponding Author	Marwan Ghosn, MD, Department of Oncology, Faculty of Medicine, Saint Joseph University, Alfred Naccache, Beirut 166830, Lebanon. marwanghosnmd@yahoo.com
Key Words	Immunotherapies; Cancers; Digestive; Checkpoint inhibitors; Gastrointestinal
Core Tip	Immune checkpoint inhibitors represent new promising anti-cancer therapies, rapidly approved in different malignancies and settings. We aimed in this editorial to report all the ongoing and published trials evaluating these agents in gastro-intestinal malignancies, to focus on the past expectations and the reality of the results and finally, to discuss the future perspectives of these agents in this field.
Publish Date	2017-05-06 20:30
Citation	Kourie HR, Tabchi S, Ghosn M. Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality. World J Gastroenterol 2017; 23(17): 3017-3021
URL	http://www.wjgnet.com/1007-9327/full/v23/i17/3017.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i17.3017

Full Article (PDF)	WJG-23-3017.pdf
Full Article (Word)	WJG-23-3017.doc
Manuscript File	29107-Review.docx
Answering Reviewers	29107-Answering reviewers.pdf
Audio Core Tip	29107-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	29107-Conflict-of-interest statement.pdf
Copyright License Agreement	29107-Copyright assignment.pdf
Peer-review Report	29107-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	29107-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	29107-Scientific misconduct check.pdf
Scientific Editor Work List	29107-Scientific editor work list.pdf